

Press Release

Joachim Weith
Senior Vice President
Corporate Communications
& Public Affairs

Fresenius SE
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2101
F +49 6172 608-2294
joachim.weith@fresenius.com
www.fresenius.com

September 30, 2008

Syndicated Credit Facilities for APP Pharmaceuticals acquisition financing increased by US\$ 500 million due to strong demand

After successfully raising more than US\$ 1,300 million from the issuance of mandatory exchangeable bonds and new shares in July and August, Fresenius has met strong reception in the general syndication phase of its Senior Secured Credit Facilities used to finance the acquisition of APP Pharmaceuticals, Inc.

Given strong demand from institutional investors, resulting in substantial oversubscription, Fresenius has increased the Facilities by US\$ 500 million to US\$ 2,950 million.

Prior to general syndication, the Facilities consisted of revolving credit facilities of US\$ 450 million with a maturity of 5 years, a US\$ 1,000 million Term Loan A with a maturity of 5 years and a US\$ 1,000 million Term Loan B with a maturity of 6 years. The Term Loan B has now been increased to US\$ 1,500 million.

Standard & Poor's today announced that the ratings of Fresenius SE and its various debt instruments remain unchanged following the US\$ 500 million increase of the Facilities.

The additional funds will be used to reduce the US\$ 1,300 million bridge credit facility which was drawn at the closing of the APP Pharmaceuticals acquisition in early September, to US\$ 800 million. The bridge credit facility has a maturity of up to 7 years.

#

About Fresenius SE

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2007, group sales were approx. € 11.4 billion. On June 30, 2008 the Fresenius Group had 117,453 employees worldwide.

For more information visit the Company's website at www.fresenius.com

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Board of Management: Dr. Ulf M. Schneider (President and CEO), Rainer Baule, Dr. Francesco De Meo, Dr. Jürgen Götz, Dr. Ben Lipps, Stephan Sturm, Dr. Ernst Wastler
Supervisory Board: Dr. Gerd Krick (Chairman)
Registered Office: Bad Homburg, Germany/Commercial Register No. HRB 10660